Coya Therapeutics to Participate at Upcoming September Investor Conferences

Rhea-AI Summary

Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company specializing in regulatory T cell (Treg) function enhancement for neurodegenerative disorders, has announced its participation in two major investor conferences in September 2025.

CEO Arun Swaminathan will present at the H.C. Wainwright Global Investment Conference on September 10 at 10 am ET at the Lotte New York Palace Hotel. The company will also attend the Lake Street Capital Markets Best Ideas Growth Conference on September 11 at The Yale Club of New York City. Management will be available for one-on-one meetings at both events.

A webcast of the presentation will be available on the company's website for 90 days.

HOUSTON, Sept. 3, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the company's management team will participate in two upcoming investor conferences this month.

H.C. Wainwright 27th Annual Global Investment Conference
Date: September 10, 2025
Time: 10 am ET
Format: Presentation by Arun Swaminathan, Ph.D., CEO of Coya Therapeutics
Location: Lotte New York Palace Hotel (455 Madison Avenue at 50th Street, New York, NY)
Webcast: https://journey.ct.events/view/6cf11632-c8ed-4aa4-999e-58a7808f0634           

Lake Street Capital Markets 9th Annual Best Ideas Growth Conference
Date: September 11, 2025
Location: The Yale Club of New York City (50 Vanderbilt Ave, New York, NY)

Coya's management team will be available for one-on-one meetings during the conferences for interested parties.

The live and archived webcast will be accessible from the Company's website at https://coyatherapeutics.com/ under the Investor Relations section - Events and Presentations. The replay of the webcast will be accessible for 90 days.

About Coya Therapeutics, Inc.
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells ("Tregs") to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases. This cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.

Coya's investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

For more information about Coya, please visit www.coyatherapeutics.com

Forward-Looking Statements
This press release contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," and similar expressions are intended to identify forward-looking statements.

Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the impact of COVID-19; the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Contact 
David Snyder, CFO
david@coyatherapeutics.com

astr partners
Matthew Beck
matthew.beck@astrpartners.com
917-415-1750

Media Contacts
Russo Partners
Olipriya Das
Olipriya.Das@russopartnersllc.com
646-942-5588

Matthew Purcell
matthew.purcell@russopartnersllc.com
646-942-5595

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/coya-therapeutics-to-participate-at-upcoming-september-investor-conferences-302544869.html

SOURCE Coya Therapeutics, Inc.

FAQ

When is Coya Therapeutics (COYA) presenting at the H.C. Wainwright Conference 2025?

Coya Therapeutics will present on September 10, 2025 at 10:00 AM ET at the Lotte New York Palace Hotel in New York.

Where can I watch Coya Therapeutics' (COYA) H.C. Wainwright conference presentation?

The presentation can be accessed via webcast on Coya's website (coyatherapeutics.com) under the Investor Relations section, and will be available for 90 days after the event.

What does Coya Therapeutics (COYA) specialize in?

Coya Therapeutics is a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders.

Which investor conferences is Coya Therapeutics (COYA) attending in September 2025?

Coya is attending the H.C. Wainwright Global Investment Conference on September 10 and the Lake Street Capital Markets Best Ideas Growth Conference on September 11, both in New York City.